Alimitha Kodali, MD
Endocrinology, Diabetes & Metabolism · Myrtle Beach, SCNPI 1275054991
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations.
Across 248 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$687
- Novo Nordisk$578
- UCB, Inc.$509
- Radius Health, Inc.$410
- Lilly USA, LLC$375
- Sanofi-aventis U.S. LLC$249
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,91199%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 43 | $687 |
| Novo Nordisk | 25 | $578 |
| UCB, Inc. | 29 | $509 |
| Radius Health, Inc. | 16 | $410 |
| Lilly USA, LLC | 22 | $375 |
| Sanofi-aventis U.S. LLC | 15 | $249 |
| Bayer | 9 | $231 |
| Dexcom, Inc. | 8 | $201 |
| Xeris Pharmaceuticals, Inc. | 12 | $191 |
| AbbVie | 8 | $141 |
| BETA Bionics, Inc. | 4 | $125 |
| Ultragenyx Pharmaceutical Inc. | 1 | $122 |
| Novartis | 8 | $116 |
| Medtronic | 1 | $98 |
| Ascensia Diabetes Care US Inc. | 4 | $88 |
| Abbott | 4 | $83 |
| Calliditas Therapeutics US Inc. | 3 | $64 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Boehringer Ingelheim | 4 | $58 |
| Aurinia Pharma U.S., Inc. | 3 | $57 |
| Corcept Therapeutics | 3 | $56 |
| Averitas Pharma Inc. | 2 | $54 |
| AstraZeneca | 3 | $49 |
| Johnson & Johnson | 2 | $38 |
| Boston Scientific | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 2 | $36 |
| Ardelyx, Inc. | 1 | $30 |
| Antares Pharma, Inc. | 1 | $25 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Mannkind Corporation | 1 | $23 |
| Medicomp Inc | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Halozyme Inc | 1 | $15 |
| Insulet Corporation | 1 | $13 |
| Cequr Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,943 in reported general payments places this provider in the 60th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 330 | $539,236 |
| MounjaroTirzepatide | 128 | $216,675 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 105 | $146,951 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $134,461 |
| JardianceEmpagliflozin | 82 | $110,627 |
| FarxigaDapagliflozin Propanediol | 95 | $108,822 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $79,175 |
| TrulicityDulaglutide | 39 | $75,971 |
| TymlosAbaloparatide | 21 | $54,635 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $35,806 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $34,670 |
| Humalog Kwikpen U-100Insulin Lispro | 90 | $29,422 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $25,531 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $23,763 |
| JanuviaSitagliptin Phosphate | 14 | $20,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $578 | $545,184345 claims |
| Lilly USA, LLCMounjaro, Trulicity | $375 | $292,646167 claims |
| Boehringer IngelheimJardiance | $58 | $110,62782 claims |
| AstraZenecaFarxiga | $49 | $108,82295 claims |
| Radius Health, Inc.Tymlos | $410 | $54,63521 claims |
| AbbVieSynthroid | $141 | $8,36289 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Myrtle Beach
- Gauri DhirMyrtle Beach$417K
- Donald EagertonMyrtle Beach$284K
- Anne LarochelleMyrtle Beach$32K
- Jocelyn MyersMyrtle Beach$26K
- Zhiwei ZhangMyrtle Beach$3K
- Paul BunnMyrtle Beach$3K
- Matthew CrabtreeMyrtle Beach$2K
- Sahana ParthasarathyMyrtle Beach$2K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.